The current recommendations to manage patients with low grade PCa is active surveillance while being carefully monitored for disease progression using PSA kinetics, periodic biopsies for histologic progression, sufficient to permit timely therapeutic intervention. This evidence concerns the gene KLK3 and posterior cortical atrophy.